Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study
The British Journal of Radiology · 2023
DOI: 10.1259/bjr.20230079 ↗Kurz gefasst
Fachartikel in der Zeitschrift The British Journal of Radiology, 2023. Verfasst von Zhouyu Ning und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms, Cholangiocarcinoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
Most patients with intrahepatic cholangiocarcinoma (ICC) present with locally advanced or metastatic disease. We report the combined potency of transarterial chemoembolization (TACE), lenvatinib and programmed cell death-1 (PD-1) inhibitors in patients with advanced and metastatic ICC.
Methods
This retrospective study enrolled 32 patients with advanced or metastatic ICC between January 2017 and August 2021. Eligible patients had received gemcitabine-based TACE combined with lenvatinib with or without PD-1 inhibitor in any line of treatment. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Risk factors associated with OS were assessed using univariate and multivariate Cox regression analyses.
Results
Eighteen patients received a combination of TACE and lenvatinib (TL group) and 14 patients received TACE and lenvatinib plus aPD-1 inhibitor (TLP group). The median follow-up time was 19.8 months (range 1.8–37.8). The median OS was 25.3 months (95% CI 18.5–32.1) and the median PFS was 7.3 months (95% CI 4.9–9.7). Partial response was achieved in 10 patients (31.3%), and stable disease in 13 (40.6 %) with disease control rate of 71.9%. The median OS was comparable in the TL and TLP groups (22.4 vs 27.3 months, respectively; hazard ratio: 1.245, 95% CI 0.4245–3.653; p = 0.687). The regression analysis revealed that, regardless of treatment group, a favorable independent prognostic factor for OS was HBV/HCV infection (HR: 0.063, 95% CI 0.009–0.463; p = 0.007). There were no treatment-related deaths and 81.3% of study participants experienced adverse events (AEs), the majority of which were of moderate severity (71.8% Grade 1–2).
Conclusions
Gemcitabine-based TACE plus lenvatinib with or without aPD-1 inhibitor was well tolerated and provided promising therapeutic outcomes for patients with advanced and metastatic ICC. Advances in knowledge: Monotherapy with TACE, or Lenvatinib, or PD-1 inhibitors has shown limited efficacy over standard first-line chemotherapy in advanced and metastatic ICC. This work suggested the combined potency of these treatments and well-tolerance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Zitieren
APA
Ning, Z., Xie, L., Yan, X., Hua, Y., Shi, W., Lin, J., Xu, L., & Meng, Z. (2023). Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study. The British Journal of Radiology. https://doi.org/10.1259/bjr.20230079
Vancouver
Ning Z, Xie L, Yan X, Hua Y, Shi W, Lin J, et al. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study. The British Journal of Radiology. 2023. doi:10.1259/bjr.20230079
BibTeX
@article{Ning2023,
author = {Ning, Zhouyu and Xie, Lin and Yan, Xia and Hua, Yongqiang and Shi, Weidong and Lin, Junhua and Xu, Litao and Meng, Zhiqiang},
title = {Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study},
journal = {The British Journal of Radiology},
year = {2023},
doi = {10.1259/bjr.20230079}
}
EUVIMED